[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vivek Bhalla\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100639457",false,"NCT07579260","IMPACT-HTN Study of Patients With Hypertension","Prospective Early Patient Experience Initiative (IMPACT-HTN)","Inclusion Criteria:\n\n* Signed and dated informed consent form\n* Ability to answer survey questions and to report blood pressure reading monthly\n* Male and female participants; 18 years or older\n* Treated with at least 2 antihypertensive therapies of different pharmacological classes for at least 4 weeks before the screening visit\n* Mean Sitting Systolic Blood Pressure (SiSBP) greater or equal to 130 mmHg\n\nExclusion Criteria:\n\n* Confirmed severe hypertension (grade 3) defined as SiSBP greater than or equal to 180 mmHg and\u002For Sitting Diastolic Blood Pressure (SiDBP) greater than or equal to 110 mmHg\n* Clinically significant unstable cardiac disease at screening or in the past in the opinion of the investigator\n* Heart failure NYHA functional class III and IV or NT-proBNP \\> 500 pg\u002FmL\n* Severe renal insufficiency or eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m2\n* Moderate to severe hepatic impairment (Child-Pugh B and C) or elevated aminotransferase (\\> 3 x ULN)","ALL","18 Years",{"count":18,"type":19},100,"ESTIMATED","97 Days","OBSERVATIONAL","An estimated 120 million people have high blood pressure (hypertension) in the US, of which approximately 10% have resistant hypertension. This study aims to enroll patients who continue to have hypertension while being treated with at least two medications. The study will follow patients for approximately 3 months and collect real-world information on changes in their health to identify an ideal patient profile that would benefit from 4th-line antihypertensive therapies, including, but not limited to, FDA-approved aprocitentan, renal denervation, mineralocorticoid receptor antagonists, etc.",[24,25,26],"Hypertension (HTN)","Hypertension","Blood Pressure, High","NOT_YET_RECRUITING","2026-06-24",{"date":30,"type":31},"2026-06-29","ACTUAL",{"date":33,"type":19},"2026-07-01",{"date":35,"type":19},"2027-04-01",{"name":37,"class":38},"Vivek Bhalla","OTHER",2,""]